50 likes | 60 Views
Global Migraine Market<br>
E N D
Global Migraine Market – Industry Trends and Forecast to 2029 In recent years, the migraine market is anticipated to grow rapidly during the forecast period. Migraine is the world's 19th most prevalent cause of disability, according to the World Health Organization. Migraine sufferers take twice as many prescription drugs and visit doctors and emergency rooms twice as often as individuals who do not suffer from the condition. Migraine sufferers have also spent significantly more on healthcare. Migraine sufferers are observed to consume 2.5 times as many prescription drugs and have six times the number of diagnostic tests and services as non-migraine sufferers. As a result of the rising occurrence of migraine, more therapies are being used to provide relief, which serves to drive the entire market. Data Bridge Market Research analyses that the migraine market was valued at USD 3.5 billion in 2021 and is expected to reach USD 4.83 billion by 2029, registering a CAGR of 4.10% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Description https://www.databridgemarketresearch.com/reports/global-migraine-market Migraine is a neurological illness that causes throbbing pain in the forehead, side of the head, or around the eyes in one person only. Autonomic symptoms such as nausea, vomiting, photophobia, and phonophobia are frequently associated with the pain. Migraine is usually diagnosed by looking at the patient's medical history and symptoms, as well as performing blood tests and MRI and CT scans. To ease the symptoms and lessen the frequency and intensity of migraine attacks, over-the-counter (OTC) medications and prescription injections are currently available. These medications are taken either on a regular basis or in response to attacks or exacerbations of chronic pain. Recent Development In September 2021, FDA had approves the first and only oral CGRP receptor antagonist named QULIPTA™ (atogepant), which is specifically developed for the preventive treatment of migraine. CGRP and its receptors are used for nervous system associated with migraine pathogenesis, and CGRP levels have been found to be higher during migraine attacks in studies. QULIPTA is a once-daily medication that blocks CGRP. It comes in three different strengths including 10 mg, 30 mg, and 60 mg.
Major Key Players • Global Migraine Market Scope • Types • Episodic • Chronic • Symptoms • Food Cravings • Depression • Fatigue • Frequent Yawning • Hyperactivity • Irritability • Neck Stiffness • Others • Treatment • Medication • Acupressure • Counseling • Hormone Therapy • Others
Market Segmentation • Some of the major players operating in the migraine market are: • F. Hoffmann-La Roche Ltd. (Switzerland) • Mylan N.V. (US) • Teva Pharmaceutical Industries Ltd.(Jerusalem) • Sanofi (France) • Pfizer Inc. (US) • GlaxoSmithKline plc (UK) • Novartis AG (Switzerland) • Bayer AG (Germany) • Eli Lilly and Company (US) • Merck & Co., Inc. (US) • Allergan (Ireland) • AstraZeneca (UK) • https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-migraine-market
About Data Bridge Market Research An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Read Continue : http://databridgemarketresearch.com/about-us/ Contact Us : SopanGedam Sopan.gedam@databridgemarketresearch.com